Image_4_GM-CSF-activated STAT5A regulates macrophage functions and inflammation in atherosclerosis.png حسب Jan Nagenborg (14771194)

"…These changes could partially be confirmed at functional level, with significant increases in apoptosis and decreases in lipid uptake and IL-6, IL-8, and TNFa cytokine secretion after STAT5A knockdown. …"

Table_1_Loss of function of VdDrs2, a P4-ATPase, impairs the toxin secretion and microsclerotia formation, and decreases the pathogenicity of Verticillium dahliae.DOCX حسب Hui Ren (122548)

"…In addition, the defect of VdDrs2 impaired the synthesis of melanin and the formation of microsclerotia, and decreased the sporulation of V. dahliae. Our data indicate a key role of P4 ATPases-associated vesicle transport in toxin secretion of disease fungi and support the importance of mycotoxins in the pathogenicity of V. dahliae.…"

Measurement of calcein leakage stimulated by short-circuiting with and without plasmid DNA. حسب Yoshino Tsurusaki (15419063)

Influence of the amount of DNA in the low-conductivity droplet on calcein leakage and gene transfection. حسب Yoshino Tsurusaki (15419063)

Decrease of the stability of the miRNAs in MVs by disrupting the association of the miRNA with Ago2 complexes. حسب Limin Li (126729)

Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study حسب Juliane Schikora (20871169)

Additional file 2 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study حسب Juliane Schikora (20871169)

Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study حسب Juliane Schikora (20871169)

S1 Fig - HET0016, a Selective Inhibitor of 20-HETE Synthesis, Decreases Pro-Angiogenic Factors and Inhibits Growth of Triple Negative Breast Cancer in Mice حسب Thaiz Ferraz Borin (507940)

METTL3 and ALKBH5 oppositely regulate m⁶A modification of <i>TFEB</i> mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes حسب Huiwen Song (755791)

"…Mechanistically, METTL3 methylates <i>TFEB</i>, a master regulator of lysosomal biogenesis and autophagy genes, at two m⁶A residues in the 3ʹ-UTR, which promotes the association of the RNA-binding protein HNRNPD with <i>TFEB</i> pre-mRNA and subsequently decreases the expression levels of TFEB. …"

Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study حسب Juliane Schikora (20871169)

Excel spreadsheet containing, in separate sheets, the underlying numerical data and statistical analysis for Figs 1A and 1B, 2, 3, 4, 5 and S1 Fig. حسب Zirui Guo (13994364)

Image_6_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_1_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_7_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_4_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_8_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_9_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_2_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"

Image_3_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF حسب Sarra El-Soussi (11228799)

"…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …"